Konruns Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  KC1036 / Konruns Pharma
    Trial completion date, Trial primary completion date, Metastases:  To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors (clinicaltrials.gov) -  Oct 17, 2024   
    P1/2,  N=133, Recruiting, 
    Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Oct 2025
  • ||||||||||  KC1036 / Konruns Pharma
    Trial completion date, Trial primary completion date, Metastases:  A Study of KC1036 in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Oct 17, 2024   
    P1,  N=207, Recruiting, 
    Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Oct 2025 Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jul 2023 --> Oct 2025
  • ||||||||||  kanitinib (CX1003) / Konruns Pharma
    Trial completion date, Trial primary completion date, Metastases:  A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Oct 17, 2024   
    P1,  N=126, Recruiting, 
    Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jul 2023 --> Oct 2025 Trial completion date: Nov 2022 --> Dec 2025 | Trial primary completion date: Nov 2022 --> Oct 2025
  • ||||||||||  KC1036 / Konruns Pharma
    Trial completion:  A Food Effect Study of KC1036 in Healthy Subjects (clinicaltrials.gov) -  Oct 10, 2023   
    P1,  N=12, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  KC1036 / Konruns Pharma
    Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_1695;    
    Results Drug screen showed that this cell line was extremely sensitive to KC1036 (IC50=4.8nm), which is a home-made small molecule inhibitor with strong anti-MET and anti-angiogensis activity. Conclusions In conclusion, we successfully established a novel NSCLC cell line (HX-JCJ) harboring MET ex14 skipping mutation from the primary tumor tissue, which may provide a promising cell model for further MET relevant research.
  • ||||||||||  KC1036 / Konruns Pharma
    Enrollment open, Metastases:  A Study of KC1036 in Patients with Advanced Thymic Tumors (clinicaltrials.gov) -  Mar 9, 2023   
    P2,  N=30, Recruiting, 
    Further studies in pts with lung adenocarcinoma would be considered promising. Not yet recruiting --> Recruiting
  • ||||||||||  KC1036 / Konruns Pharma
    Trial completion date, Trial primary completion date, Metastases:  A Study of KC1036 in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Jan 4, 2023   
    P1,  N=207, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2023
  • ||||||||||  KC1036 / Konruns Pharma
    Enrollment open, Trial initiation date, Metastases:  To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors (clinicaltrials.gov) -  Jan 3, 2023   
    P1/2,  N=133, Recruiting, 
    Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2023 Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Jan 2022
  • ||||||||||  kanitinib (CX1003) / Konruns Pharma
    Trial primary completion date, Metastases:  A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Jan 14, 2022   
    P1,  N=126, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Jan 2022 Trial primary completion date: Nov 2021 --> Nov 2022
  • ||||||||||  KC1036 / Konruns Pharma
    Enrollment change, Metastases:  A Study of KC1036 in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Aug 18, 2021   
    P1,  N=207, Recruiting, 
    Trial primary completion date: Nov 2021 --> Nov 2022 N=108 --> 207
  • ||||||||||  KC1036 / Konruns Pharma
    Enrollment open, Metastases:  A Study of KC1036 in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Sep 8, 2020   
    P1,  N=108, Recruiting, 
    N=108 --> 207 Not yet recruiting --> Recruiting
  • ||||||||||  kanitinib (CX1003) / Konruns Pharma
    Trial completion, Enrollment change, Metastases:  Kanitinib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Sep 3, 2020   
    P1,  N=9, Completed, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Completed | N=45 --> 9
  • ||||||||||  CX1106 / Konruns Pharma
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases:  KC-DIAO-004: Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Sep 2, 2020   
    P2,  N=0, Withdrawn, 
    Not yet recruiting --> Completed | N=45 --> 9 N=30 --> 0 | Trial completion date: Dec 2022 --> Mar 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2021 --> Mar 2020
  • ||||||||||  kanitinib (CX1003) / Konruns Pharma
    Enrollment open, Metastases:  A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Sep 2, 2020   
    P1,  N=126, Recruiting, 
    N=30 --> 0 | Trial completion date: Dec 2022 --> Mar 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2021 --> Mar 2020 Not yet recruiting --> Recruiting